Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Published:2018-05 Issue:3 Volume:24 Page:344-347
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Collins P. W.¹^ORCID,Liesner R.²,Makris M.³^ORCID,Talks K.⁴,Chowdary P.⁵^ORCID,Chalmers E.⁶^ORCID,Hall G.⁷,Riddell A.⁵,Percy C. L.⁸,Hay C. R.⁹^ORCID,Hart D. P.¹⁰

Affiliation:

1. School of Medicine; Cardiff University; UK

2. Great Ormond Street Hospital; London UK

3. University of Sheffield; Sheffield UK

4. Royal Victoria Infirmary; Newcastle UK

5. Royal Free Hospital; London UK

6. Royal Hospital for Children; Glasgow UK

7. John Radcliffe Hospital; Oxford UK

8. Queen Elizabeth Hospital; Birmingham UK

9. Central Manchester University Hospitals; Manchester UK

10. Barts and The London School of Medicine and Dentistry; Queen Mary University London; Royal London Hospital; London UK

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13495/fullpdf

Reference11 articles.

1. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model;Kitazawa;Nat Med,2012

2. Emicizumab Prophylaxis in Hemophilia A with Inhibitors;Oldenburg;N Engl J Med,2017

3. Emicizumab, a bispecific antibody recognising coagulation factors IX and X: how does it actually compare to factor VIII?;Lenting;Blood,2017

4. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edn). UK Haemophilia Centre Doctors Organization;Collins;Br J Haematol,2013

5. https://www.gene.com/download/pdf/hemlibra_prescribing.pdf

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience;Hematology Reports;2023-11-01

2. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

3. Clinical pharmacology of emicizumab for the treatment of hemophilia A;Expert Review of Clinical Pharmacology;2023-08-21

4. The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study;Orphanet Journal of Rare Diseases;2023-08-03

5. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO);Haemophilia;2023-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3